Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
This paper was processed by another editor and underwent a rigorous peer-review process
Diabetes Therapy 15(7):16391646 Yabe D, et al (2020) Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
For cardiovascular risk reduction, Wegovy may still be an optionit was FDA-approved for reducing heart attack and stroke risk in March 2024
Shop CopperTheory
Trulicity (dulaglutide) EPAR Summary of Product Characteristics
US$ 26.98
US$ 26.00
US$ 27.26
US$ 27.36
